Cue Biopharma (CUE) Debt/Equity Ratio: History & Chart

Cue Biopharma, Inc.(CUE)

Biotechnology · Boston, MA

$24.09-0.27 (-1.11%)

Delayed quote: Oct 6, 2026, 10:59 AM EDT

About Cue Biopharma, Inc.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.

Boston, MA

29 employees

www.cuebiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Shao-Lee Lin

View full financials

CUE Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

3.81

DEBT TO EQUITY RATIO AVG TTM

1.00

DEBT TO EQUITY RATIO AVG 3Y

0.43

DEBT TO EQUITY RATIO AVG 5Y

0.33

DEBT TO EQUITY RATIO AVG 10Y

0.20

DEBT TO EQUITY RATIO AVG 15Y

N/A

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+279.97%

CURRENT VS 3Y AVG

+781.06%

CURRENT VS 5Y AVG

+1059.38%

CURRENT VS 10Y AVG

+1779.54%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.13

median of 567 covered companies

CURRENT VS SECTOR MEDIAN

+2832.73%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Cue Biopharma, Inc. (CUE)	$175.00M	3.81	1.00	0.43	0.33
MediWound Ltd. (MDWD)vs ›	$172.90M	0.27	0.21	0.17	0.19
Precision BioSciences, Inc. (DTIL)vs ›	$172.79M	0.62	0.42	0.73	0.54
Nkarta, Inc. (NKTX)vs ›	$172.07M	0.30	0.22	0.24	0.18
Compass Therapeutics, Inc. (CMPX)vs ›	$178.38M	0.06	0.05	0.03	0.07
Journey Medical Corporation (DERM)vs ›	$179.09M	0.80	1.04	1.07	0.91
OptimizeRx Corp. (OPRX)vs ›	$168.70M	0.15	0.24	0.19	0.13
Organogenesis Holdings Inc. (ORGO)vs ›	$170.29M	0.23	0.21	0.33	0.41
Canton Strategic Holdings Inc (CNTN)vs ›	$181.62M	0.00	0.00	0.00	0.00
Oramed Pharmaceuticals Inc. (ORMP)vs ›	$183.14M	0.00	0.00	0.08	0.07

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Cue Biopharma, Inc. (CUE)

$175.00M

3.81

1.00

0.43

0.33

MediWound Ltd. (MDWD)vs ›

$172.90M

0.27

0.21

0.17

0.19

Precision BioSciences, Inc. (DTIL)vs ›

$172.79M

0.62

0.42

0.73

0.54

Nkarta, Inc. (NKTX)vs ›

$172.07M

0.30

0.22

0.24

0.18

Compass Therapeutics, Inc. (CMPX)vs ›

$178.38M

0.06

0.05

0.03

0.07

Journey Medical Corporation (DERM)vs ›

$179.09M

0.80

1.04

1.07

0.91

OptimizeRx Corp. (OPRX)vs ›

$168.70M

0.15

0.24

0.19

0.13

Organogenesis Holdings Inc. (ORGO)vs ›

$170.29M

0.23

0.21

0.33

0.41

Canton Strategic Holdings Inc (CNTN)vs ›

$181.62M

0.00

Oramed Pharmaceuticals Inc. (ORMP)vs ›

$183.14M

0.00

0.08

0.07

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Cue Biopharma, Inc. (CUE)?

The debt to equity ratio for CUE stock is 3.81.

Is Cue Biopharma, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 3.81 is 1059% above its 5-year average of 0.33, near the high end of its 5-year range (0.06–3.81).

What is the TTM average debt to equity ratio for Cue Biopharma, Inc. (CUE)?

The TTM average debt to equity ratio for CUE stock is 1.00.

What is the 3Y average debt to equity ratio for Cue Biopharma, Inc. (CUE)?

The 3Y average debt to equity ratio for CUE stock is 0.43.

What is the 5Y average debt to equity ratio for Cue Biopharma, Inc. (CUE)?

The 5Y average debt to equity ratio for CUE stock is 0.33.

What is the 10Y average debt to equity ratio for Cue Biopharma, Inc. (CUE)?

The 10Y average debt to equity ratio for CUE stock is 0.20.

DATE	DEBT TO EQUITY RATIO
2026-06-30	3.81
2026-03-31	0.16
2025-12-31	0.16
2025-09-30	0.47
2025-06-30	0.42
2025-03-31	1.08
2024-12-31	0.51
2024-09-30	0.37
2024-06-30	0.52
2024-03-31	0.43
2023-12-31	0.40
2023-09-30	0.38
2023-06-30	0.39
2023-03-31	0.34
2022-12-31	0.29
2022-09-30	0.45
2022-06-30	0.33
2022-03-31	0.31
2021-12-31	0.18
2021-09-30	0.06
2021-06-30	0.07
2021-03-31	0.09
2020-12-31	0.09
2020-09-30	0.09
2020-06-30	0.11
2020-03-31	0.10
2019-12-31	0.11
2019-09-30	0.26
2019-06-30	0.39
2019-03-31	0.35
2018-12-31	0.00
2018-09-30	0.00
2018-06-30	0.00
2018-03-31	0.04
2017-12-31	0.04
2017-09-30	0.00
2017-06-30	0.00
2017-03-31	0.00
2016-12-31	0.00
2016-09-30	0.00
2016-06-30	0.00
2016-03-31	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

3.81

2026-03-31

0.16

2025-12-31

0.16

2025-09-30

0.47

2025-06-30

0.42

2025-03-31

1.08

2024-12-31

0.51

2024-09-30

0.37

2024-06-30

0.52

2024-03-31

0.43

2023-12-31

0.40

2023-09-30

0.38

2023-06-30

0.39

2023-03-31

0.34

2022-12-31

0.29

2022-09-30

0.45

2022-06-30

0.33

2022-03-31

0.31

2021-12-31

0.18

2021-09-30

0.06

2021-06-30

0.07

2021-03-31

0.09

2020-12-31

0.09

2020-09-30

0.09

2020-06-30

0.11

2020-03-31

0.10

2019-12-31

0.11

2019-09-30

0.26

2019-06-30

0.39

2019-03-31

0.35

2018-12-31

0.00

2018-09-30

0.00

2018-06-30

0.00

2018-03-31

0.04

2017-12-31

0.04

2017-09-30

0.00

2017-06-30

0.00

2017-03-31

0.00

2016-12-31

0.00

2016-09-30

0.00

2016-06-30

0.00

2016-03-31

0.00

Debt to Equity Ratio: 3.81

CUE Debt to Equity Ratio

CUE Average Debt to Equity Ratio Chart

CUE Current vs Average Debt to Equity Ratio Chart

CUE Debt to Equity Ratio Metrics

CUE Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

CUE Debt to Equity Ratio History

Related Metrics